Phase I study of XELOXIRI(CPT-11,L-OHP, capecitabine) with Bevacizumab in patients with unresectable advanced/metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2620878
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: Patients receive infusional CPT-11,L-OHP, bevacizumab, and oral capecitabine every 21 days.
Primary outcome(s): Safety
Study Design: Single arm Non-randomized
创建时间：
2010-04-15
